What is Fluidic Sciences?
Fluidic Sciences, originating from the University of Cambridge in 2013, specializes in the design, development, and manufacturing of innovative tools for the rapid and accurate characterization of proteins. The company operates at the intersection of biotechnology and advanced engineering, providing essential solutions for laboratory, medical, and consumer applications. By focusing on the fundamental challenges of protein analysis, Fluidic Sciences addresses critical bottlenecks in drug discovery and diagnostic development. Its market position is defined by its deep-tech roots and its commitment to translating academic research into scalable, commercial-grade instrumentation that meets the rigorous demands of global life science sectors.
How much funding has Fluidic Sciences raised?
Fluidic Sciences has raised a total of $40.3M across 3 funding rounds:
Series A
$2.4M
Series B
$6.9M
Unspecified
$31M
Series A (2015): $2.4M with participation from Amadeus Capital Partners, Cambridge Enterprise, Parkwalk Advisors, and DFJ Esprit
Series B (2016): $6.9M led by Cambridge Enterprise, Cambridge Innovation Capital, IQ Capital Partners, Amadeus Capital Partners, Parkwalk Advisors, and Molten
Unspecified (2018): $31M supported by IQ Capital, Amadeus Capital Partners, BGF, Delin Ventures, and Molten
Key Investors in Fluidic Sciences
IQ Capital Partners
A Cambridge and London-based venture capital firm specializing in deep-tech investments, including machine learning, robotics, and disruptive algorithms.
Amadeus Capital Partners
A global technology venture capital firm that supports high-growth companies from seed to later stages across sectors like artificial intelligence and digital health.
Parkwalk Advisors
A leading investor in university spinouts, focusing on bridging the gap between academic research and commercial success in deep-tech and health-tech sectors.
What's next for Fluidic Sciences?
Looking ahead, the strategic deployment of the $31M capital is expected to accelerate the commercialization of the company's core technology platform. As Fluidic Sciences transitions into a more mature lifecycle stage, the focus will likely shift toward expanding its global footprint and deepening its penetration into clinical and consumer diagnostic markets. The continued support from institutional investors suggests a long-term strategy centered on product diversification and the establishment of new industry standards for protein analysis. By maintaining its focus on high-precision engineering and data-driven insights, the company is well-positioned to capitalize on the increasing demand for rapid, point-of-care diagnostic tools in an evolving healthcare landscape.
See full Fluidic Sciences company page
